The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
RenJie JinDouglas W StrandConnor M ForbesThomas CaseJustin M M CatesQi LiuMarisol Ramirez-SolanoGinger L MilneStephanie SanchezZunyi Y WangDale E BjorlingNicole L MillerRobert J MatusikPublished in: The Prostate (2021)
Treatment of BPH/LUTS by inhibition of alpha-adrenergic receptors with pharmaceutical α-blockers or inhibiting androgenesis with 5ARI may fail because of elevated paracrine signaling by prostatic PGs that can cause smooth muscle contraction. In contrast to patients who fail medical therapy for BPH/LUTS, control I-BPH patients do not show the same evidence of elevated PG pathway signaling. Elevation of the PG pathway may explain, in part, why the risk of clinical progression in the MTOPS study was only reduced by 34% with α-blocker treatment.
Keyphrases
- benign prostatic hyperplasia
- lower urinary tract symptoms
- smooth muscle
- end stage renal disease
- healthcare
- magnetic resonance
- ejection fraction
- chronic kidney disease
- newly diagnosed
- signaling pathway
- prostate cancer
- peritoneal dialysis
- computed tomography
- prognostic factors
- combination therapy
- angiotensin converting enzyme